Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > 7500000

<< Previous

Bullboard Posts

Next >>

Comment by Momo25on Dec 22, 2022 5:33pm

150 Views

Post# 35188162

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:7500000

You are very correct. In few weeks, you will see again the SPECEO alike chanting again Aleluia Th is back with the start of a very promising new Phase 1-b and/or an extarordinary Nash program.

<< Previous

Bullboard Posts

Next >>

Crypto and blockchain stock ends year with a profit